Osimertinib Frontline for EGFR Mutated Resistance Mechanisms Not Fully Understood

Osimertinib Frontline for EGFR Mutated Resistance Mechanisms Not Fully Understood

thoraciconcology

1 year
216 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Anne S. Tsao, MD of MD Anderson Cancer Center discusses Osimertinib in front-line for EGFR mutated resistance mechanisms and how they are not fully understood. New data of Osimertinib showing with progression free and overall survival benefit in the front-line setting, Dr. Tsao is giving Osimertinib for newly diagnosed EGFR mutated patients. However, the resistance mechanism for patients who receive Osimertinib front-line is not yet fully understood. There are reports that the C797S mutation maybe important and more data is needed to know whats the best treatment for those who are refractory to Osimertinib. One can always do chemotherapy and subsequent other therapies, like the EGFR targeted therapy or clinical trials with EGFR targeted agents. For Dr. Tsao she reserves immunotherapy for further down the line for EGFR oncogenic driver mutated patients. For her patients who are currently on first generation EGFR TKI, Dr. Tsao is not switching to Osimertinib if they respond very well. So, she is following the standard protocol for these patients when patients are in first generation or second generation, testing them when they progress to see their resistance mechanism. If patients have T790, Osimertinib will be the best. However, if they have other oncogenic driver mutations, another specific agent should be fit for them. On the other hand, if patients have progressional disease, its very important to go with chemotherapy or if its slow growth, Dr, Tsao suggest Bevacizumab to the first and second generation EGFR TKI patients to control their disease.
Up Next Autoplay
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Category: News
0 Views
Cancer-News 1 hour
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
0 Views
kidneycancer 2 hours
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
0 Views
kidneycancer 3 hours
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
1 Views
kidneycancer 22 hours
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
4 Views
Cancer-News 1 day
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 1 day
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
3 Views
kidneycancer 1 day
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
2 Views
Cancer-News 1 day
Management of Clinical Cases in Kidney Cancer
Management of Clinical Cases in Kidney Cancer
Category: Kidney Cancer
4 Views
kidneycancer 2 days
Kidney Cancer Program & SPORE
Kidney Cancer Program & SPORE
Category: Kidney Cancer
1 Views
kidneycancer 2 days